Wednesday, December 20, 2017 1:05:57 PM
Lane Simonian
Posted: Sunday, March 5, 2017 10:31 PM
Joined: 12/12/2011
Posts: 4066
Microglia (the brain's main immune cells) are likely over-activated during the early stages of Alzheimer's disease leading to inflammation but damaged as the disease progresses:
New research suggests that Alzheimer’s disease (AD) could be caused by the degeneration of microglia, the cells in the central nervous system that normally protect neurons...
This new hypothesis challenges the theory that AD is the result of amyloid protein deposits in the brain that trigger an inflammatory reaction. According to this theory, the inflammatory response activates microglial cells to produce toxic substances that in turn cause neurons to degenerate. This inflammation theory has been implicated not only in AD but in other neurological diseases, including Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease.
"If people are claiming that these activated microglia kill neurons by producing toxins of various kinds, then I should expect to see these activated microglia right next to the dying neurons," said lead author and microglia expert Wolfgang J. Streit, PhD, from the department of neuroscience at the McKnight Brain Institute at the University of Florida College of Medicine, in Gainesville.
"But when I looked in those regions, I couldn't find a single activated microglial cell," he told Medscape Neurology. "What I found instead were microglial cells that were breaking apart, fragmenting into many little pieces."
These observations might help explain why anti-inflammatory drugs do not seem to prevent or diminish dementia, he suggests. And if borne out, they could result in a reevaluation of current treatment approaches for AD.
Inflammation may play a role in Alzheimer's disease (activated microglia, for instance, add to oxidative stress), but its role may decline as the disease continues. Furthermore, the damage done to microglia by oxidative stress may prevent them from removing toxins from the brain.
Recent IGXT News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 10:25:33 PM
- Form 253G2 - • Edgar (US Regulatory) • 02/20/2024 07:07:33 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 02/20/2024 05:15:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 10:22:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:12:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:12:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 08:58:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 08:56:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 08:56:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 08:55:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 08:52:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 08:51:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 08:50:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 08:48:53 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/11/2023 09:16:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 01:26:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 09:18:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:11 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/16/2023 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 08:01:53 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/06/2023 08:00:26 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 09/07/2023 01:22:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/06/2023 01:00:17 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM